Clinical Trial Update: Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update assessing efficacy and safety of BCD-063 and Copaxone-Teva in relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BCD-063
• Copaxone-Teva (glatiramer acetate)

Snippet

Sponsor: Biocad | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 3 | Status: COMPLETED